FORA Capital LLC Raises Position in Henry Schein, Inc. (NASDAQ:HSIC)

FORA Capital LLC lifted its stake in Henry Schein, Inc. (NASDAQ:HSIC) by 76.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 21,763 shares of the company’s stock after acquiring an additional 9,412 shares during the quarter. FORA Capital LLC’s holdings in Henry Schein were worth $1,587,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Clarkston Capital Partners LLC boosted its position in shares of Henry Schein by 5.4% in the third quarter. Clarkston Capital Partners LLC now owns 1,397,805 shares of the company’s stock worth $101,900,000 after buying an additional 71,560 shares during the period. Nuance Investments LLC boosted its holdings in Henry Schein by 22.3% in the third quarter. Nuance Investments LLC now owns 2,278,081 shares of the company’s stock valued at $166,072,000 after purchasing an additional 414,748 shares during the last quarter. Thompson Siegel & Walmsley LLC purchased a new position in Henry Schein in the second quarter valued at about $46,683,000. SG Americas Securities LLC boosted its holdings in Henry Schein by 1,622.3% in the third quarter. SG Americas Securities LLC now owns 458,828 shares of the company’s stock valued at $33,449,000 after purchasing an additional 432,187 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Henry Schein in the third quarter valued at about $515,000. Hedge funds and other institutional investors own 96.62% of the company’s stock.

Insider Transactions at Henry Schein

In related news, COO Michael S. Ettinger sold 12,240 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $75.00, for a total value of $918,000.00. Following the sale, the chief operating officer now directly owns 87,706 shares in the company, valued at $6,577,950. This trade represents a 12.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now owns 71,833 shares in the company, valued at approximately $4,978,026.90. This represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

Henry Schein Trading Up 0.5 %

NASDAQ:HSIC opened at $77.66 on Thursday. The company has a quick ratio of 0.82, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average is $71.15 and its two-hundred day moving average is $69.78. The company has a market cap of $9.68 billion, a PE ratio of 31.96, a P/E/G ratio of 2.20 and a beta of 0.87. Henry Schein, Inc. has a 52 week low of $63.67 and a 52 week high of $82.63.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. The business had revenue of $3.17 billion for the quarter, compared to analysts’ expectations of $3.24 billion. Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The business’s quarterly revenue was up .4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.32 EPS. On average, analysts predict that Henry Schein, Inc. will post 4.78 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on HSIC. UBS Group reduced their price target on Henry Schein from $75.00 to $72.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Robert W. Baird reduced their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. JPMorgan Chase & Co. reduced their price target on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, August 12th. StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $82.00 target price on shares of Henry Schein in a report on Wednesday, November 6th. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $79.38.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.